Van Andel Research Institute (VARI) researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment. Kidney cancer is among the 10 most common cancers in both men and women, striking nearly 50,000 Americans in 2009 and killing more than 11,000... 
More...
More...